Zobrazeno 1 - 10
of 227
pro vyhledávání: '"Angelica, Selim"'
Autor:
Matthias Gromeier, Darell D Bigner, Smita K Nair, David Boczkowski, Michael C Brown, Karenia Landa, Sin-Ho Jung, Georgia M Beasley, Norma E Farrow, Maria Angelica Selim, Rami N Al-Rohil, Aaron D Therien, Junheng Gao, Eda K Holl
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 10, Iss 9 (2022)
Background We previously reported results from a phase 1 study testing intratumoral recombinant poliovirus, lerapolturev, in 12 melanoma patients. All 12 patients received anti-PD-1 systemic therapy before lerapolturev, and 11 of these 12 patients al
Externí odkaz:
https://doaj.org/article/04605eb95ab14089a2829c1d83ca4646
Autor:
Matthias Gromeier, Darell D Bigner, Smita K Nair, Karenia Landa, Sin-Ho Jung, Georgia M Beasley, Norma E Farrow, Maria Angelica Selim, Carol Ann Wiggs, Andrea True Kelly, April KS Salama
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 4 (2021)
Background While programmed cell death protein 1 (PD-1) and programmed death-ligand 1 (PD-L1) antagonists have improved the prognosis for many patients with melanoma, around 60% fail therapy. PVSRIPO is a non-neurovirulent rhinovirus:poliovirus chime
Externí odkaz:
https://doaj.org/article/e28cb6ceb21645b987a84e695f9c4187
Autor:
Joanna P. Wróblewska, Dora Dias-Santagata, Adam Ustaszewski, Cheng-Lin Wu, Masakazu Fujimoto, M. Angelica Selim, Wojciech Biernat, Janusz Ryś, Andrzej Marszalek, Mai P. Hoang
Publikováno v:
Cells, Vol 10, Iss 9, p 2216 (2021)
Background: The prognostic value of commonly recurrent mutations remains unclear in mucosal melanomas. Methods: Clinicopathologic parameters of 214 cases of mucosal melanomas diagnosed in 1989–2020 in several clinical institutions were analyzed. NR
Externí odkaz:
https://doaj.org/article/ecfb73e88a5a4fe68e81a3afa87628e2
Publikováno v:
Dermatology Online Journal. 29
Autor:
Jennifer Y. Zhang, M. Angelica Selim, Benjamin Leshin, Jane Y. Jin, Shazia Lutfeali, Paula Miliani de Marval
CYLD has been recognized as a tumor suppressor due to its dominant genetic linkage to multiple types of epidermal tumors and a range of other cancers. The molecular mechanisms governing CYLD control of skin cancer are still unclear. Here, we showed t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ea2f5cea16e2accd219ad2de209bdde9
https://doi.org/10.1158/1940-6207.c.6544523
https://doi.org/10.1158/1940-6207.c.6544523
Autor:
Jennifer Y. Zhang, M. Angelica Selim, Benjamin Leshin, Jane Y. Jin, Shazia Lutfeali, Paula Miliani de Marval
Supplementary Figures and Legends from CYLD Inhibits Tumorigenesis and Metastasis by Blocking JNK/AP1 Signaling at Multiple Levels
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4bef9cccc318274ec7a1adc910c6188e
https://doi.org/10.1158/1940-6207.22524995.v1
https://doi.org/10.1158/1940-6207.22524995.v1
Autor:
Douglas S. Tyler, Francis Ali-Osman, Scott K. Pruitt, James Padussis, Nicole McMahon, Georgia M. Beasley, James Burchette, M. Angelica Selim, Yasunori Yoshimoto, Jin S. Yoo, Patricia A. Zipfel, Sin-Ho Jung, Hiroaki Toshimitsu, Christina K. Augustine
Melanoma responds poorly to standard chemotherapy due to its intrinsic chemoresistance. Multiple genetic and molecular defects, including an activating mutation in the BRaf kinase gene, are associated with melanoma, and the resulting alterations in s
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7404e94a0c77875aa38e15e70fe0cfc9
https://doi.org/10.1158/1535-7163.c.6532047.v1
https://doi.org/10.1158/1535-7163.c.6532047.v1
Autor:
Douglas S. Tyler, Francis Ali-Osman, Scott K. Pruitt, James Padussis, Nicole McMahon, Georgia M. Beasley, James Burchette, M. Angelica Selim, Yasunori Yoshimoto, Jin S. Yoo, Patricia A. Zipfel, Sin-Ho Jung, Hiroaki Toshimitsu, Christina K. Augustine
Supplementary Table 1 from Sorafenib, a Multikinase Inhibitor, Enhances the Response of Melanoma to Regional Chemotherapy
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f2c94ea8aab669189c7435adb095ca7f
https://doi.org/10.1158/1535-7163.22485684.v1
https://doi.org/10.1158/1535-7163.22485684.v1
Autor:
David M. Brizel, Walter T. Lee, Douglas S. Tyler, Kent J. Weinhold, John S. Yi, Katelyn N. Steadman, Chelsae Dumbauld, Paul J. Mosca, Georgia M. Beasley, Brent A. Hanks, David S. Yoo, Brian G. Czito, Kristen N. Linney, M. Angelica Selim, Christel N. Rushing, Manisha Palta, April K.S. Salama
Trial Schema
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9a54eaadf546155af4cce495323463ee
https://doi.org/10.1158/1078-0432.22478619.v1
https://doi.org/10.1158/1078-0432.22478619.v1
Autor:
David M. Brizel, Walter T. Lee, Douglas S. Tyler, Kent J. Weinhold, John S. Yi, Katelyn N. Steadman, Chelsae Dumbauld, Paul J. Mosca, Georgia M. Beasley, Brent A. Hanks, David S. Yoo, Brian G. Czito, Kristen N. Linney, M. Angelica Selim, Christel N. Rushing, Manisha Palta, April K.S. Salama
Purpose:In this prospective trial, we sought to assess the feasibility of concurrent administration of ipilimumab and radiation as adjuvant, neoadjuvant, or definitive therapy in patients with regionally advanced melanoma.Patients and Methods:Twenty-
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::be9513f567ef445d0169f1bd8a14404a
https://doi.org/10.1158/1078-0432.c.6530004
https://doi.org/10.1158/1078-0432.c.6530004